Mutation of KRAS in colorectal adenocarcinoma in Greenland

KRAS mutation is one of the most frequent driver mutations in colorectal cancer (CRC) and is also a prognostic biomarker. The aim of the present study was to determine the frequency of KRAS mutations over time in the Greenlandic population diagnosed with CRC. In total, 578 patients with the diagnosi...

Full description

Bibliographic Details
Published in:APMIS
Main Authors: Mousavi, Nabi, Truelsen, Sarah Line Bring, Bernth-Andersen, Simon, Koch, Anders, Heegaard, Steffen
Format: Article in Journal/Newspaper
Language:English
Published: 2022
Subjects:
Colorectal cancer
greenland
inuit
KRAS mutation
population genetics
Greenland
greenlandic
Online Access:https://curis.ku.dk/portal/da/publications/mutation-of-kras-in-colorectal-adenocarcinoma-in-greenland(0bd60c8c-f32d-47bf-9e3e-fd20e181913a).html
https://doi.org/10.1111/apm.13254
https://curis.ku.dk/ws/files/329417639/IKM_APMIS_2022_Mousavi_Mutation_of_KRAS_in_colorectal_adenocarcinoma_in_Greenland.pdf
Description
Summary:KRAS mutation is one of the most frequent driver mutations in colorectal cancer (CRC) and is also a prognostic biomarker. The aim of the present study was to determine the frequency of KRAS mutations over time in the Greenlandic population diagnosed with CRC. In total, 578 patients with the diagnosis of adenocarcinoma between 1988 and 2017 were identified. The status of KRAS and the mutational subtypes of KRAS mutations were determined in 102 representative samples by the Idylla™ platform in the time periods 1988–1990, 2002–2004, and 2015–2017. The results showed that the frequency of the KRAS mutations increased significantly, from 27% in 1988–1990 to 43% in 2015–2017 (p < 0.001). Furthermore, the most frequent subtypes of KRAS mutations in Greenland were G12D (c.35G > A) with 14%, G12V (c.35G > T) with 7%, and G13D (c.38G > A) with 6%. In conclusion, this study showed that the frequency of KRAS mutations in CRC has been increasing in recent decades in the specific population of Greenland. The results of this study may be used in initiatives related to targeted therapy of CRC in specific ethnicities and in investigations focusing on the environmental factors of cancer-related somatic mutations.

Similar Items